Caffeine therapy for apnea of prematurity

Schmidt, Barbara; Roberts, Robin S; Davis, Peter; Doyle, Lex W; Barrington, Keith J; Ohlsson, Arne; Solimano, Alfonso; Tin, Win; Pfister, Riccardo

doi:10.1056/NEJMoa054065

Scientific article

English

Caffeine therapy for apnea of prematurity

ContributorsSchmidt, Barbara; Roberts, Robin S; Davis, Peter; Doyle, Lex W; Barrington, Keith J; Ohlsson, Arne; Solimano, Alfonso; Tin, Win; Pfister, Riccardo

Published inThe New England journal of medicine, vol. 354, no. 20, p. 2112-2121

Publication date2006

Abstract

Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.

Keywords

Apnea/drug therapy/therapy
Bronchopulmonary Dysplasia/prevention & control
Caffeine/pharmacology/therapeutic use
Central Nervous System Stimulants/pharmacology/therapeutic use
Combined Modality Therapy
Female
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases/drug therapy
Infant, Very Low Birth Weight
Logistic Models
Male
Oxygen Inhalation Therapy
Respiration, Artificial
Weight Gain/drug effects

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research groups

Réanimation néonatale en salle d'accouchement (696)

Citation (ISO format)

SCHMIDT, Barbara et al. Caffeine therapy for apnea of prematurity. In: The New England journal of medicine, 2006, vol. 354, n° 20, p. 2112–2121. doi: 10.1056/NEJMoa054065

Article (Published version)

Identifiers

PID : unige:46930
DOI : 10.1056/NEJMoa054065
PMID : 16707748

Journal ISSN0028-4793

1603views

2750downloads

Creation29/01/2015 16:45:00

First validation29/01/2015 16:45:00

Update time14/03/2023 23:52:05

Status update14/03/2023 23:52:04

Last indexation30/10/2024 23:58:21

Archive ouverte UNIGE

Caffeine therapy for apnea of prematurity

Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.

Technical informations